country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-13892

Copy Link Print Information

Dovitinib dilactic acid

(Synonyms: CHIR-258 dilactic acid; TKI258 dilactic acid)

11 Cited Publications

Customer Review

Based on 11 publication(s) in Google Scholar

Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis.

For research use only. We do not sell to patients.

CAS No.: 852433-84-2
Formula: C₂₇H₃₃FN₆O₇
Molecular Weight:572.59

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (275 KB)

Dovitinib dilactic acid Chemical Structure

CAS No.: 852433-84-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Clinical Trial
Chemical Information
Publications (11)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All VEGFR Isoforms :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 852433-84-2
Molecular Weight 572.59
Formula C₂₇H₃₃FN₆O₇
SMILES

CC(O)C(O)=O.CC(O)C(O)=O.O=C1NC2=C(C(F)=CC=C2)C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3
Synonyms

CHIR-258 dilactic acid; TKI258 dilactic acid
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (11)

All WB

Sort by:

Journal Impact Factor

Nat Commun

PEAK1 maintains tight junctions in intestinal epithelial cells and resists colitis by inhibiting autophagy-mediated ZO-1 degradation. [Abstract]

2025 Jul 24;16(1):6777. PMID: 40707483
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Theranostics

Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway. [Abstract]

2018 Jul 30;8(15):4262-4278. PMID: 30128052

Dovitinib dilactic acid purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]

BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefinitib at 2.5 µM, Sunitinib at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.
Acta Pharm Sin B

2026 Feb 10.
NPJ Precis Oncol

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. [Abstract]

2021 Jul 16;5(1):66. PMID: 34272467
Front Cell Dev Biol

An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. [Abstract]

2020 May 7:8:287. PMID: 32457900

Dovitinib dilactic acid purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2020 May 7:8:287. [Abstract]

Determination in L3.6 cells of FGF2-induced FGFR phosphorylation by Western blot in the presence of Dovitinib. FGFR1 and alpha-Tubulin are used as loading controls.
J Biol Chem

Activation of Gcn2 by small molecules designed to be inhibitors. [Abstract]

2023 Apr;299(4):104595 PMID: 36898579
BMJ Open Ophthalmol

Impact of anticancer drugs on human Tenon's fibroblast proliferation: implications for glaucoma surgery. [Abstract]

2026 Jan 12;11(1):e002307. PMID: 41526033
University of Düsseldorf

2024.
bioRxiv

2024 June 09.
Biochemistry for Health, NOVA University of Lisbon

2019 Jul.

Solvent & Solubility

In Vitro:

DMSO : ≥ 30 mg/mL (52.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7465 mL

8.7323 mL

17.4645 mL

5 mM

0.3493 mL

1.7465 mL

3.4929 mL

10 mM

0.1746 mL

0.8732 mL

1.7465 mL

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhu, S., et al. The Chemical Development of CHIR-258. CHIMIA International Journal for Chemistry, 60(9), 584–592.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7465 mL	8.7323 mL	17.4645 mL	43.6613 mL
	5 mM	0.3493 mL	1.7465 mL	3.4929 mL	8.7323 mL
	10 mM	0.1746 mL	0.8732 mL	1.7465 mL	4.3661 mL
	15 mM	0.1164 mL	0.5822 mL	1.1643 mL	2.9108 mL
	20 mM	0.0873 mL	0.4366 mL	0.8732 mL	2.1831 mL
	25 mM	0.0699 mL	0.3493 mL	0.6986 mL	1.7465 mL
	30 mM	0.0582 mL	0.2911 mL	0.5822 mL	1.4554 mL
	40 mM	0.0437 mL	0.2183 mL	0.4366 mL	1.0915 mL
	50 mM	0.0349 mL	0.1746 mL	0.3493 mL	0.8732 mL

Keywords

Dovitinib dilactic acid

11 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- Clinical Trial
Chemical Information
Publications (11)
Solvent & Solubility
- In Vitro
Purity & Documentation
References

1/16
1/16

Dovitinib dilactic acid purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2020 May 7:8:287. [Abstract]

Customer Validation
Determination in L3.6 cells of FGF2-induced FGFR phosphorylation by Western blot in the presence of Dovitinib. FGFR1 and alpha-Tubulin are used as loading controls.
1/16

Dovitinib dilactic acid purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]

Customer Validation
BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefinitib at 2.5 µM, Sunitinib at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Dovitinib dilactic acid

Publications Citing Use of MedChemExpress (MCE) Dovitinib dilactic acid

All VEGFR Isoforms

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dovitinib dilactic acid Related Classifications

HY-13892 Related Classifications